Oxidative stress is implicated in the pathogenesis of many diseases; however, currently used antioxidants have a high toxicity that constrains administration to a narrow window of therapeutic dosage. There is a clear need for more effective and safer antioxidants. Diatomic hydrogen (H 2 ) was proposed as a novel antioxidant that selectively reduces levels of toxic reactive-oxygen species. Recently, many studies have reported that H 2 (inhaled or orally ingested, typically as approximately 0.8 mM H 2 -saturated water), can exert beneficial effects in diverse animal models of ischaemia-reperfusion injury, and inflammatory and neurological disease. In the clinic, oral administration of H 2saturated water is reported to improve lipid and glucose metabolism in subjects with diabetes or impaired glucose tolerance; promising results have also been obtained in reducing inflammation in haemodialysis patients and treating metabolic syndrome. These studies suggest H 2 has selective antioxidant properties, and can exert antiapoptotic, antiinflammatory and antiallergy effects. This review summarizes recent research findings and mechanisms concerning the therapeutic potential of H 2 .
Introduction
Oxidative stress is a feature of many conditions including ischaemia-reperfusion (I/R) injury, inflammatory disorders, cancer, cardiovascular and neurological diseases, and ageing. 1 Oxidative stress is generally associated with the production of highly reactive free radicals including reactive oxygen species (ROS). The mitochondrion is the primary source of ROS, and much research has focused on the identification of naturally occurring low-toxicity antioxidants that can target mitochondrial ROS. Although a relatively unexplored field of medicine, increasing attention is now being paid to the potential use of medicinal gases as therapeutic agents. 2, 3 This article reviews recent work, in pre-clinical models and clinical trials, on the use of diatomic hydrogen (H 2 ) -a naturally occurring biomolecule -as a selective antioxidant. Y Hong, S Chen, J-M Zhang Hydrogen as a selective antioxidant with unpaired electrons in an open shell configuration; these unpaired electrons make the radical species highly chemically reactive. ROS include superoxide anion (O 2 -•), hydroxyl radical (•OH), hydrogen peroxide (H 2 O 2 ) and singlet oxygen ( 1 O 2 ). These different species interconvert via cascade reactions.
Although generally regarded as toxic byproducts, physiological roles have been identified for molecules such as H 2 O 2 and the nitric oxide radical (NO•), 4 which have been shown to play important roles as effector molecules in immune defence systems against pathogens, and as signalling molecules. 5, 6 For this reason, the elimination of all types of ROS through powerful antioxidant therapies is likely to disrupt important cellular functions. Indeed, it has been reported that radical suppression of oxidative stress can promote tumour progression. 7 Nevertheless, overproduction of several types of ROS has been associated with a range of toxic effects. The majority of these effects have been associated with the hydroxyl radical •OH, one of the most reactive of the ROS species, 8 which can indiscriminately damage cellular components including lipid, protein, carbohydrate and nucleic acid, ultimately leading to cellular necrosis and apoptosis. This raises the prospect of developing selective antioxidants that preferentially remove toxic radicals such as •OH, but not others (such as H 2 O 2 or NO•). 4 The accumulation of ROS is generally counterbalanced by a sophisticated endogenous antioxidant defence system that comprises enzymes -such as superoxide dismutase (SOD), catalase and glutathione peroxidase -and non-enzymes, such as vitamin A, vitamin C, carotene and bilirubin. Although O 2 -• and H 2 O 2 can be detoxified by antioxidant defence enzymes,
•OH cannot be detoxified by this route. This has emphasized the importance of antioxidants targeting •OH. Approximately 4000 antioxidants have been described to date, most of which are electron donors that react with ROS to form harmless end-products such as water. Although many have given promising results in animal models of oxidative stress, in most cases the beneficial effects seen in animal studies have not been reiterated in clinical trials. 9 Barriers to the utilization of exogenous antioxidants include low membrane permeability and high toxicity, which constrain administration to a narrow window of therapeutic dosage. 10 The identification of a novel and more effective antioxidant is, therefore, of high priority.
Rationale behind H 2 : a selective antioxidant
It has long been known that H 2 -a colourless, odourless and tasteless gas -has antioxidant properties, but the potential exploitation of H 2 as a therapeutic agent has only recently been explored in animal models and in the clinic. The first study, by Dole et al. 11 reported that there was significant cancer regression in patients with squamous cell carcinoma exposed to hyperbaric H 2 for 2 weeks. In 2001, hyperbaric H 2 was reported to be beneficial in the treatment of schistosomiasisassociated chronic liver inflammation, and its therapeutic properties were ascribed to scavenging of •OH. 12 These studies were not, however, extended by other researchers, perhaps in view of the explosion hazards associated with hydrogen. Nevertheless, it is important to note that such risks are eliminated when used in H 2 /air mixtures of < 4.6% (v/v). 12 Ohsawa et al. 13 studied the antioxidant properties of molecular H 2 and reported that it selectively reduces •OH and Y Hong, S Chen, J-M Zhang Hydrogen as a selective antioxidant ONOObut does not affect physiological ROS. Subsequent studies 14 -20 confirmed that the beneficial effects of H 2 are principally mediated by •OH scavenging ( Fig. 1 ).
H 2 as a therapeutic agent: review of animal models and clinical trials
The discovery by Ohsawa et al. 13 that inhalation of H 2 gas can protect the brain against oxidative stress associated with I/R prompted a series of studies in diverse models, exploring the potential of H 2 inhalation (or oral ingestion of H 2 -saturated water) to reduce oxidative damage. These studies, summarized in Table 1 , 14 -43 have targeted a diverse range of disorders and organ systems including the nervous, digestive, cardiovascular and respiratory systems. In the following sections, reports on H 2 therapy in different disease classes are reviewed.
ISCHAEMIA-REPERFUSION INJURY
Oxidative stress is thought to play a major role in cell damage following I/R injury and several studies have addressed whether H 2 administration can reduce I/R-induced cell 
1: Evidence for therapeutic use of diatomic hydrogen (H 2 ) in various diseases and its effects on various markers

Marker
Models of disease H 2 effect References
Antioxidase SOD Radiation complication, metabolic Qian et al., 14 Nakao et sepsis, obstructive jaundice al., 15 Xie et al., 16 Liu et al. 17 
CAT
Sepsis, obstructive jaundice Xie et al., 16 Liu et al. 17 
GSH
Radiation complication Qian et al. 14 
Oxidative
MDA I/R (hepatic, intestinal, neonatal Fukuda et al., 18 Zheng et stress hypoxia, cardiac, renal), Alzheimer's al., 19 Mao et al., 20 Cai et disease, cognitive disorders, al., 21 Chen et al., 22 Sun pancreatitis, atherosclerosis, et al., 23 Nakao et al., 24 obstructive jaundice, radiation and
Cardinal et al., 25 Li et al., 26 
chemotherapy complication, spinal
Nagata et al., 27 Chen et cord injury al., 28 Ohsawa et al., 29 Liu et al., 17 Qian et al., 14 Nakashima-Kamimura et al., 30 Chen et al. 31 
4HNE
Atherosclerosis, Parkinson's disease, Ohsawa et al., 29 Fu et Alzheimer's disease, cognitive al., 32 Fujita et al., 33 Li et disorders, I/R (renal and retinal), al., 26 Nagata et al., 27 haemorrhagic Cardinal et al., 25 Oharazawa et al., 34 Chen et al. 35 
8-OHdG I/R (cerebral, myocardium, retinal,
Ohsawa et al., 13 Hayashida renal), Parkinson's disease, et al., 36 Sun et al., 23 haemorrhagic, metabolic syndrome, Oharazawa et al., 34 
radiation complication
Shingu et al., 37 Fu et al., 32 Chen et al., 35 Nakao et al., 15 Qian et al. 14 
MPO
Intestinal I/R injury, sepsis, Zheng et al., 19 Chen et pancreatitis, haemodialysis, al., 22 Chen et al., 28 Xie et obstructive jaundice, spinal cord al., 16 Nakayama et al., 38 injury Liu et al., 17 Chen et al. 31 
8-oxoG
Parkinson's disease Fujita et al. 33 
8-isoPGF 2α Sepsis, metabolic syndrome
Xie et al., 16 Nakao et al. 15 
DAO
Intestinal I/R injury Zheng et al. 19 
TBARs
Metabolic syndrome Nakao et al. 15 
NADPH Allergic
Itoh et al. 39 
Inflammation IL-1β
Intestinal I/R, colon inflammation, Buchholz et al., 40 Zheng et factor obstructive jaundice al., 19 Mao et al., 20 Kajiya et al., 41 Liu et al. 17 
IL-6
Intestinal I/R, Alzheimer's disease, Buchholz et al., 40 Zheng et renal transplantation, obstructive al., 19 Li et al., 26 Cardinal et jaundice al., 25 Liu et al. 17 
TNF-α
Intestinal I/R, Alzheimer's disease, Zheng et al., 19 Mao et colon inflammation, renal al., 20 Li et al., 26 Kajiya et transplantation, obstructive al., 41 Cardinal et al., 25 Liu jaundice, hepatitis et al., 17 Kajiya et al. 42 ¦
Y Hong, S Chen, J-M Zhang Hydrogen as a selective antioxidant loss in animal models. H 2 was reported to protect against I/R injury in models of cerebral, 13, 21, 43 myocardial, 24, 36 hepatic, 18 intestinal, 22,40 retinal 34 and renal 37 I/R. H 2 was also reported to reduce infarct size in rat models of focal cerebral and myocardial ischaemia, 13, 36 maintain the integrity of the blood-brain barrier and reduce haemorrhagic transformation in a rat model of focal ischaemia. 35 The beneficial effects of H 2 treatment are likely to be due to direct scavenging of •OH, although the kinetic favourability of this direct reaction has not been established. It was observed, however, that in biochemical studies of I/R injury, H 2 treatment was able to reduce the levels of multiple markers of oxidative stress. Notably, H 2 decreased the 16 Nakao et al., 24 jaundice Liu et al. 17 
PCNA
Pancreatitis, intestinal I/R Chen et al., 28 Chen et al. 22 
IFN-γ
Hepatitis, renal transplantation Kajiya et al., 42 36 Chen et neonatal hypoxia), chemotherapy al., 22 Cai et al., 21 Cai et complication, spinal cord injury, al., 43 Nakashimapancreatitis Kamimura et al., 30 Chen et al., 31 Chen et al. 28 
Annexin V Radiation complication
Qian et al. 14 
Caspase-3 Neonatal hypoxia, myocardium
Cai et al., 43 Cai et al., 21 
I/R injury, spinal cord injury
Sun et al., 23 Nakao et al., 24 Chen et al. 31 
Caspase-12 Neonatal hypoxia, spinal cord injury
Cai et al., 43 23, 34, 36 These results argue that H 2 has significant antioxidant effects in I/R injury. Furthermore, I/R injury is commonly associated with cell death in the ischaemic region as a result of apoptosis and/or necrosis. Importantly, it has been reported that H 2 treatment can significantly reduce the numbers of terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick-end labelling (TUNEL)positive cells in parallel with reductions in the levels of activated caspases 3 and 12, 23, 34 arguing that the protective effects of H 2 are mediated in part through inhibition of pathways of programmed cell death.
The above studies, which were all doubleblind and placebo-controlled, suggest that the use of H 2 for I/R is effective. Clinical application of H 2 during I/R is slight, so we speculated whether clinical studies would also show encouraging results. In our opinion, the therapeutic window for I/R disease is usually very short. When translated into a clinical application, H 2 must be most frequently applied as early as possible in the treatment of patients with acute infarction. It is particularly important to make sure that H 2 can rapidly reach 'atrisk' ischaemic areas before blood flow in the occluded infarct-related artery is reestablished. Consequently, further research is warranted to enhance the application of H 2 for curing I/R injury.
INFLAMMATORY DISEASE
Inflammatory processes are known to be closely linked with oxidative stress, and several studies have addressed the potential of H 2 as an anti-inflammatory therapeutic.
In inflammatory conditions, H 2 treatment was found significantly to reduce levels of interleukin (IL)-6 and tumour necrosis factor-α (TNF-α), as well as levels of other inflammation-associated molecules including intercellular adhesion molecule-1, IL-12, high-mobility group box 1 and interferonγ 16,23,25,28,40 -42 in rodent models. Importantly, H 2 partly inhibited mitogen-activated protein kinase signalling pathways, including c-Jun N-terminal kinase (JNK), p38, extracellular signal-regulated protein kinase (ERK1/2), as well as upstream kinase cascades. 25 In animal models of inflammatory disorders, it has been reported that H 2 can attenuate inflammation in hepatitis, 42 colitis, 41 pancreatitis, 28 obstructive jaundice 17 and sepsis. 16 H 2 treatment was also associated with the downregulation of the expression of proinflammatory cytokines and suppression of inflammatory cell infiltration (summarized in Table 1 ).
NEUROLOGICAL DISEASE
In a rat model of Parkinson's disease, 6hydroxydopamine (6-OHDA) induced oxidative stress in dopaminergic neurons, leading to nigrostriatal degeneration. 32 Fu et al. 32 first examined the effects of oral administration of 50% H 2 -saturated water before intrastriatal injection of 6-OHDA, and found that H 2 significantly reduced the extent of degeneration. More recently, a lower concentration of orally administered H 2 (5% saturated H 2 in drinking water) was found to prevent DNA damage and lipid peroxidation, and to reduce dopaminergic neuron loss in a MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxin model of Parkinson's disease. 33 In Alzheimer's disease it is thought that amyloid β (Aβ), the major component of Y Hong, S Chen, J-M Zhang Hydrogen as a selective antioxidant senile plaques, plays a causal role in disease development, and exerts its toxic effects in part via the induction of oxidative stress. 26 Oral administration of H 2 -saturated water has been reported to attenuate Aβ-induced deficits, in a rat model. 26 It was also reported that H 2 could improve spatial recognition and memory, and that this was accompanied by reduced levels of proinflammatory cytokines, lipid peroxidation products and glial fibrillary acidic protein immunoreactivity. 26 Furthermore, in a different animal model (restraint-induced stress) H 2 administration was found to alleviate stress-induced deficits in learning and memory. 27 Oxidative stress, inflammation and apoptosis are also central features of cell loss following acute spinal cord contusion. Using an animal model, H 2 treatment led to improved rates of functional locomotor recovery after spinal cord injury; this recovery was associated with reduced oxidative stress and elevated brain-derived neurotrophic factor levels. 31 Gu et al. 44 reported that daily consumption of H 2saturated water was effective in preventing age-related learning and memory impairments; this effect was attributed to removal of ROS and increased SOD activity.
METABOLIC DISORDERS
Metabolic syndrome refers to a common disorder characterized by a combination of obesity, dyslipidaemia, hypertension and insulin resistance. These metabolic disorders are suitable for clinical research with H 2 because of their chronic characteristics. Consequently, clinical studies of H 2 are, at present, mostly limited to metabolic diseases. Nakao et al., 15 in an open-label pilot study involving 20 subjects with potential metabolic syndrome, demonstrated that consumption of 1.5 -2.0 l/day of H 2 -saturated water for 8 weeks reduced the levels of oxidative stress indicators. Moreover, the treated subjects showed significant improvements in liver and kidney function. In addition to direct antioxidant effects, it was reported that H 2 enhanced SOD levels, thereby increasing endogenous antioxidant defence against O 2 -•. The sample in this study was, however, so small that the finding should be accepted with caution. 15 In a randomized, double-blind, placebo-controlled, crossover study, Kajiyama et al. 45 reported that supplementation with 900 ml/day of H 2saturated water for 8 weeks reduced the levels of several biomarkers of oxidative stress, including plasma oxidized low-density lipoprotein cholesterol and urinary 8isoprostanes, and also improved glucose metabolism in patients with either type 2 diabetes or impaired glucose tolerance; however, their breath hydrogen levels were not reported in detail after consumption. Supplementation with H 2 -saturated water normalized the oral glucose tolerance test in four out of six patients with impaired glucose tolerance. 45 Furthermore, consumption of H 2 ad libitum was reported to prevent the development of atherosclerosis in apolipoprotein E knockout mice, partly through its ability to limit oxidative stress in blood vessels. 29 The efficacy of H 2 -saturated water in these studies appeared to be significantly greater than other tested antioxidants including folic acid, vitamin E, iron and α-lipoic acid.
CHEMOTHERAPY, HAEMODIALYSIS AND RADIOTHERAPY COMPLICATIONS
Reagents such as cisplatin, which target rapidly proliferating cells, are widely used to treat aggressive neoplastic conditions. Nevertheless, cisplatin use is restricted Y Hong, S Chen, J-M Zhang Hydrogen as a selective antioxidant because of its major side-effects during therapy, some of which have been ascribed to oxidative stress and/or inflammation. Using an animal model, Nakashima-Kamimura et al. 30 reported that both oral consumption of H 2 -saturated water, as well as H 2 administration by inhalation, could alleviate cisplatin-induced nephrotoxicity without compromising antitumour activity.
In a non-randomized study with a concurrent control, Nakayama et al. 38 found that adding H 2 to haemodialysis solutions after a 1-month run-in period ameliorated inflammatory reactions, decreased plasma oxidative markers and improved blood pressure control during a 6-month trial. The study period was, however, short and the inflammatory conditions of the subjects were not very serious. Thus, long-term studies on patients with more severe inflammation may be optimal for clarifying the impact of H 2 .
Excess exposure to ionizing radiation causes a spectrum of tissue damage known as acute radiation syndrome. Importantly, it has been estimated that 60% -70% of ionizing radiation-induced cellular damage is caused by •OH. 46 However, levels of apoptotic cells, plasma MDA and intestinal 8-OHdG were significantly decreased when cells or mice were treated with H 2 after irradiation. 14 This suggests that H 2 administration could also be of benefit in cancer radiotherapy.
In summary, H 2 can counter side-effects commonly seen during chemo therapy, radiotherapy and haemodialysis, thereby improving the patient's quality of life.
ALLERGIC DISEASES
Immediate-type allergic reactions include pollinosis, bronchial asthma and urticaria, which are conditions that have not been causally associated with oxidative stress. Nevertheless, it is possible that H 2 exerts therapeutic effects that are independent of the removal of •OH. Itoh et al. 39 reported that H 2 attenuated degranulation by suppressing FcεRI-mediated signal transduction in a mast-cell culture model. Administration of H 2 down-regulated antigen-induced phosphoryla tion of FcεRI-associated Lyn -a key regulatory step in the pathway -and suppressed activation of downstream signal targets including Syk, phospholipase C (PLC)-γ1, PLCγ2, Akt, ERK1/2, JNK, p38 and cytosolic phospholipase A 2 , without affecting the levels of the immunoglobulin E receptor FcεRIβ. It is, therefore, possible that H 2 can intervene in specific signal transduction pathways.
H 2 : advantages over pharmaceutical drugs
Diatomic hydrogen has several potential advantages, compared with pharmaceutical drugs ( Table 2 ). The administration of H 2 , either as a low percentage H 2 /air mixture or as a solution in water or saline, has several advantages over conventional antioxidants. First, H 2 has not been reported to be toxic at effective dosages, and overdosing is unlikely because excess H 2 is expired via the lungs. 44 This contrasts with antioxidants, such as vitamins C and E, where the effective dosage in humans is higher than the upper limit of tolerated intake. Secondly, H 2 selectively scavenges the most aggressive ROS, •OH, but is far less effective against O 2 -• and H 2 O 2 , which play physiological roles. Moreover, there is no evidence that H 2 , a mild antioxidant, is able to disturb metabolic redox reactions or to disrupt cell signalling mediated by less potent ROS. Indeed, H 2 does not influence physiological parameters such as temperature, blood pressure, pH or pO 2 . Thirdly, because of its low molecular weight, H 2 can diffuse extremely rapidly into tissue and is likely to reach important target Y Hong, S Chen, J-M Zhang Hydrogen as a selective antioxidant subcellular compartments, including mitochondria and the nucleus. This is particularly important because mitochondria are the primary sites of the generation of ROS after I/R and are notoriously difficult to target. Nuclear targeting could also be important in protecting DNA from oxidative damage. Finally, it seems likely that H 2 offers significant advantages in terms of cost compared with conventional pharmaceuticals.
Future prospects: many unsolved problems
Although multiple studies have demonstrated that H 2 administration can be effective against a range of disorders, both in animal models and in the clinic, many questions remain. At the molecular level, it is unclear how H 2 achieves chemical selectivity in view of the enormous diversity of potential molecular targets in vivo. Moreover, the published rate constant for the reaction of •OH with H 2 to form H 2 O and H• is markedly slower than for most radical-radical reactions. Intriguingly, there are some indications that H 2 might not act exclusively as an antioxidant and could also interact directly with specific signalling pathways, 39 as previously discovered for other simple gases including NO, CO and H 2 S. Further work will be required to determine the in vivo molecular targets for H 2 .
The protective effects of H 2 have been established in both animal models and clinical trials; however, none of the published studies has examined the concentration of H 2 in the active site. Further monitoring of H 2 concentrations in injury would be helpful to understand the pharmacokinetics in more detail. In Japan, H 2 therapy has been used clinically in diabetes, the metabolic syndrome and haemodialysis, but further appropriately designed, large-scale, placebo-controlled trials using different dosages and routes of administration will be required to evaluate the therapeutic efficacy of H 2 treatment rigorously in these and other conditions. Delivery of high concentrations of H 2 gas by inhalation has major drawbacks in view of the risks associated with its flammability and the complex apparatus required for safe delivery. Nagata et al. 27 first reported that consumption of H 2 -saturated water could afford a safe and effective alternative to inhalation. Nevertheless, the pharmacokinetics of different routes of administration have not been studied in depth, although Fu et al. 32 reported that arterial H 2 concentrations following consumption of 0.4 mM hydrogen water were similar to those achieved on inhalation of 2% (v/v) hydrogen gas. It seems likely that oral administration of H 2 solution will be the route of choice in further studies on the antioxidant properties of H 2 .
We have reviewed a large number of studies, principally in animal models, in which H 2 administration reduced tissue injury associated with oxidative stress and inflammation. Despite important differences between animal models and human disease, we argue that the therapeutic potential of H 2 -a non-toxic, convenient, safe and effective antioxidant -warrants further clinical evaluation in oxidative stress-related diseases.
